Some studies11,12 have suggested that guideline changes could have important implications for overdiagnosis; for example, PSA testing rates declined in the US following the 2012 USPSTF recommendation against PSA screening, which coincided with a decrease in early stage cancers detected, potentially diminishing rates of overdiagnosis. This evidence concerns the gene KLK3 and cancer.